MSK Continues on Groundbreaking Path in Treatment of Mesothelioma

Prasad S. Adusumilli, MD
Published: Wednesday, Jul 23, 2014
Memorial Sloan-Kettering Cancer CenterPrasad S. Adusumilli, MD
Prasad S. Adusumilli, MD
Deputy Chief, Thoracic Service
Memorial Sloan Kettering Cancer Center
New York, NY Dr. Yixuan Gong
Although malignant pleural mesothelioma (MPM) remains a rare disease, Memorial Sloan Kettering Cancer Center has considerable experience with this malignancy, and our specialists are at the forefront of translating new approaches for the treatment of patients with mesothelioma into the clinic.

At Memorial Sloan Kettering, patients with mesothelioma are managed by a working group that consists of specialists from multiple disciplines who use a personalized approach to achieve accurate diagnosis, stage, and treatment stratification. In general, patients with suspected mesothelioma are often misdiagnosed, owing to a lack of pathological expertise and the selection of inappropriate biopsies.

Memorial Sloan Kettering is one of the nation’s largest tertiary referral centers for this disease, and our mesothelioma working group, which meets regularly to discuss all patients with mesothelioma undergoing treatment at our center, has the skills and knowledge to ensure optimal management is consistently achieved.

Establishing Management Paradigms

Our experience with this rare tumor includes the largest study published to date (945 patients) on long-term outcomes among patients with mesothelioma at a single center. The development and maintenance of this vast and meticulous database enables us to design a customized management algorithm for each patient.

For example, to determine the most appropriate surgical resection for each patient, we employ an algorithm that takes into account the potential resectability of the tumor and the individual’s cardiopulmonary reserve—an approach that ensures tolerance of the planned surgical approach and results in better functional outcomes.

Figure 1

hemithoracic pleural intensity

A hemithoracic pleural intensity-modulated radiation therapy plan (coronal view) for a right-sided malignant pleural mesothelioma is used for targeted treatments that spare healthy lung tissue

The database has also enabled us to establish patient-management paradigms that have subsequently been adopted by physicians and official medical associations throughout the world.

Through our approach of systematically evaluating each patient with mesothelioma by CT scan, PET scan, and lung function tests, we are able to optimize patients for surgical resection and avoid unnecessary surgery that may delay treatment. Our preoperative assessment skills reflect our extensive research on these imaging modalities.1 With the assistance of Memorial Sloan Kettering radiologists, we are now developing advanced imaging techniques to accurately quantify tumor burden and monitor therapy response.

Working in concert with Memorial Sloan Kettering pathologists, our mesothelioma researchers have identified the key morphological characteristics that drive progression of mesothelioma. These developments have helped inform the efforts of the World Health Organization and other international associations to reclassify mesothelioma.2,3

Pioneering Surgical Techniques

Mesothelioma patients with early-stage disease are managed by curative-intent surgical resection, using either extrapleural pneumonectomy or pleurectomy and decortication. Our surgeons pioneered these techniques and have trained surgeons across the globe on using them.

In carefully selected patients, extrapleural pneumonectomy— which involves the removal of the involved lung lining, heart lining, nearby lymph nodes, and diaphragm—provides an excellent option. The expertise of our nursing and surgical floor staff is key in successfully managing these patients in the immediate postoperative period.

The majority of mesothelioma patients undergo pleurectomy and decortication—a lung-sparing surgical procedure that aggressively and carefully removes the tumor—so that they can quickly recover and then undergo chemotherapy and/or radiation therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication